Non-AIDS-defining cancers in people living with HIV.

Competing Interests: J-PS has received consultant or advisory role fees or meeting invitations from Roche, Merck Sharp & Dohme, Bristol Myers Squibb, Lilly, AstraZeneca, Daiichi-Sankyo, Mylan, Novartis, Pfizer, Pierre Fabre Oncology, LeoPharma, and Gilead; and a grant from MSDAvenir. JC has received research funding or grant support for clinical trials from AstraZeneca, Pfizer, Novartis, and AbbVie; and consultancy or advisory board fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Sanofi, Jansen, Merck Sharp & Dohme, Novartis, Roche, and Takeda. All other authors declare no competing interests.